Sydney M Crago

The DR:EAM trial will evaluate topically delivered OTT166 eye drops in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.

The company plans to share the first-in-human safety data from the Phase 2/3 SIGLEC trial evaluating intravitreal AVD-104.

The oral presentation, entitled “Population Pharmacokinetics and Safety of OPT-302, an anti-VEGF-C/-D ‘trap’ in Patients with Retinal Vascular Diseases” will take place on July 31, 2023 in Seattle, Washington.

Apellis has announced that seven abstracts will be presented at the American Society of Retina Specialists Annual Scientific Meeting including safety and efficacy data for the company’s pegcetacoplan injection for geographic atrophy (GA).

This certifies that the facility adheres to a comprehensive set of regulatory standards as set by the NABP to ensure safety of drugs and medical devices in the US.

The drug, known as XIPERE in the US, is used to treat uvietic macular edema and goes by the name Arcatus when licensed by Clearside Biomedical’s partner in China, Arctic Vision.

Naor is stepping down to pursue new opportunities and will be replaced by Kenneth Sall, MD who has been appointed as Opthea’s Senior Medical Advisor.

This allosteric tyrosine kinase (TYK2) inhibitor may help to treat the disregulation of TYK2 mediated pathways may also play an important role in conditions, including noninfectious uveitis.

This trial is testing tinlarebant, a novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to geographic atrophy (GA).

The PHOTON study demonstrates the long-term efficacy and safety of this treatment for patients with DME.

This investigational new drug application was cleared for the company’s phase I/II clinical trial.

The fellowship is a one-year program that will provide comprehensive training to residency graduates in the latest advancements in ophthalmology, including diagnostic and therapeutic techniques, surgical procedures, and clinical research.

Intergalactic's non-viral gene therapy platform is designed to overcome limitations of standard adeno-associated virus (AAV) gene therapy technologies.

The two-hour event will share details on the company’s clinical programs for retina diseases through formal presentations and a live Q&A session.

The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD.

Get caught up on the approvals and hear directly from Kaushal Solanki, PhD, Founder and CEO of Eyenuk.

The company announced the Complete Letter Response from the FDA for the Biologics License Application for aflibercept 8 mg is “solely due to an ongoing review of inspection findings at a third-party filler.”

The study will include 100 patients with the aim of determining effective and ineffective standards of eye injections for AMD to better personalize future medical evaluations.

The certification will allow 20/20 Onsite to make clinical trials more accessible to patients nationwide and expand site options for sponsors while maintaining performance and data collection standards, including BCVA and DR testing.

This phase will evaluate UNITY’s UBX1325 (foselutoclax) in a head-to-head comparison with aflibercept for the treatment of diabetic macular edema (DME).

Modern Retina is looking back at the first half of 2023 as we explore the role of AI in the retinal field in anticipation of the changes to come.

EyeBio has begun the dosing of the first participants in its Phase 1b/2 AMARONE clinical trial for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

The open source article reports on the anti-inflammatory compound and its potential to treat retinal diseases.

This approval will allow Belite Bio to initiate the phase 3 clinical trial in South Korea, also known as the DRAGON study.

This two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus CoQ10 combines the exact nutrient formula recommended by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression.

The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.

The company’s pipeline includes treatments for XLRP, AMD, and cone-rod dystrophy (CRD).

OTX-TKI is the Ocular Therapeutix’s axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.

Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.

PAVIA is a 12-month, randomized, controlled phase 2 clinical trial of EYP-1901 in patients with moderate to severe NPDR.